• Return to Headlines

Shares of Vanda Pharmaceut Rank the Highest in Terms of Future Earnings Growth in the Biotechnology Industry (VNDA, BMRN, AMAG, GHDX, PDLI)

By Amy Schwartz

Below are the three companies in the Biotechnology industry with the highest future earnings growth. The growth of earnings per share (next fiscal year estimated vs. current fiscal year estimated) is important to gauge future profitability and relative value. Higher EPS growth generally justifies higher earnings multiples.

Vanda Pharmaceut ranks highest with a future earnings growth of 221.5%. Following is Biomarin Pharmac with a future earnings growth of 191.3%. Amag Pharmaceuti ranks third highest with a future earnings growth of 116.3%.

Genomic Health I follows with a future earnings growth of 111.4%, and Pdl Biopharma In rounds out the top five with a future earnings growth of 84.9%.

SmarTrend recommended that its subscribers protect gains by selling shares of Pdl Biopharma In on April 25th, 2019 by issuing a Downtrend alert when the shares were trading at $3.38. Since that call, shares of Pdl Biopharma In have fallen 30.7%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.

Keywords: highest future earnings growth vanda pharmaceut biomarin pharmac amag pharmaceuti genomic health i pdl biopharma in

Ticker(s): VNDA BMRN AMAG GHDX PDLI